Table 2.
Echocardiography parameters
| Total (n = 74) |
NLR < 2.58 at T2 (n = 30) |
NLR ≥ 2.58 at T2 (n = 44) |
p Value | |
|---|---|---|---|---|
| Baseline echocardiography at T1 | ||||
| LVEF (%), mean ± SD | 60 ± 1.2 | 59 ± 0.9 | 60 ± 1.3 | .31 |
| LV GLS (%), mean ± SD | −21.61 to 1.95 | −21.46 to 1.93 | −21.72 ± 1.97 | .58 |
| LV GLS > (−18)%, n (%) | 2 (2.7) | 0 (0) | 2 (4.5) | .51 |
| LVEDD (mm), median (IQR) | 44 (42–46) | 43 (41–45) | 45 (42–47) | .08 |
| IVS (mm), median (IQR) | 9 (8–10) | 9 (8–11) | 9 (8–10) | .12 |
| LAVI (ml/m2), median (IQR) | 27 (22–33) | 26 (22–35) | 27 (23–33) | .62 |
| TAPSE (mm), mean ± SD | 24.8 ± 3.5 | 25.0 ± 3.6 | 24.6 ± 3.5 | .62 |
| Diastolic dysfunction ≥ Grade 2, n (%) | 2 (6.7) | 2 (6.7) | 0 (0) | .16 |
| LV GLS changes from T1 to T3 | ||||
| Absolute LV GLS reduction, mean ± SD | 1.9 ± 1.9 | 1.3 ± 1.7 | 2.3 ± 2.1 | .03 |
| Relative LV GLS reduction (%), mean ± SD | 8.7 ± 8.8 | 6.1 ± 6.9 | 10.6 ± 9.6 | .02 |
| LV GLS relative reduction ≥ 10%, n (%) | 28 (38) | 6 (20) | 22 (50) | .009 |
Note: Bold values are significant p < .05.
Abbreviations: IQR, interquartile range; IVS, interventricular septum; LAVI, left atrial volume index; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricle ejection fraction; LV GLS, left ventricular global longitudinal strain; NLR, neutrophil‐to‐lymphocyte ratio; SD, standard deviation; T1, baseline before doxorubicin therapy; T2, during doxorubicin exposure; T3, at the end of doxorubicin therapy; TASPE, tricuspid annular plane systolic excursion.